ID

27452

Description

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate

Keywords

Versions (2)
  1. 11/15/17 11/15/17 -
  2. 11/26/17 11/26/17 -
Copyright Holder

GlaxoSmithKline

Uploaded on

November 15, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Concomitant Medications GSK study Prostatic neoplasms NCT00883909

English

Concomitant Medications GSK study Prostatic neoplasms NCT00883909

1 forms  
Administrative data
Description

Administrative data

Session number
Description

Session number

Data type

integer

Subject number
Description

Subject number

Data type

text

Intake of concomitant Medications
Description

Intake of concomitant Medications

Were any chronic concomitant medications taken by the subject during the Follow-Up study?
Description

Check that either the YES or NO box at the top of the page is selected. • If NO is selected, check that no applicable concomitant medications are present. • If YES is selected, check that at least one applicable concomitant medication is present. If YES, record below.

Data type

text

Record of Concomitant Medications
Description

Record of Concomitant Medications

Drug (Trade name preferred)
Description

Check that the drug name (trade name preferred) is spelled correctly. If medication is given to treat a serious adverse event (SAE), then the event must be recorded on the SERIOUS ADVERSE EVENT page(s).

Data type

text

Dose
Description

Dose

Data type

float

Units
Description

Units

Data type

text

Frequency
Description

Frequency

Data type

text

Route
Description

Route

Data type

text

Date Started
Description

Check that either the ‘Date started’ is completed or ‘started Pre-Follow Up Study’ is completed. At least one must be completed, but it is acceptable if both are completed. • If both ‘Date started’ and ‘started Pre-Follow Up Study’ are completed, check that the start date is pre-study.

Data type

date

Started Pre- Follow Up Study
Description

Check that either the ‘Date started’ is completed or ‘started Pre-Follow Up Study’ is completed. At least one must be completed, but it is acceptable if both are completed. • If both ‘Date started’ and ‘started Pre-Follow Up Study’ are completed, check that the start date is pre-study.

Data type

boolean

Date Stopped
Description

Check that either the ‘Date stopped’ box is completed or the ‘continued Post-Follow Up Study’ is completed. Only one must be completed. • Check that the drug start date is before or equal to the drug stop date.

Data type

date

Continued Post- Follow Up Study
Description

Check that either the ‘Date stopped’ box is completed or the ‘continued Post-Follow Up Study’ is completed. Only one must be completed.

Data type

boolean

Conditions Treated / Indication
Description

Indication

Data type

text

Prophylaxis
Description

Prophylaxis

Data type

text

Was drug administered for an SAE?
Description

If the concomitant medication was taken for a serious adverse event (SAE), check that the event is entered on the SERIOUS ADVERSE EVENT page(s) and that the dates are consistent with the event.

Data type

text

Back to the top of the page

Similar models

Concomitant Medications GSK study Prostatic neoplasms NCT00883909

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative data
Session number
Item
Session number
integer
Subject number
Item
Subject number
text
Item Group
Intake of concomitant Medications
Item
Were any chronic concomitant medications taken by the subject during the Follow-Up study?
text
concomitant medications intake
Code List
Were any chronic concomitant medications taken by the subject during the Follow-Up study?
CL Item
Yes (Y)
CL Item
No (N)
Item Group
Record of Concomitant Medications
Drug
Item
Drug (Trade name preferred)
text
Dose
Item
Dose
float
Units
Item
Units
text
Frequency
Item
Frequency
text
Route
Item
Route
text
Date Started
Item
Date Started
date
Started Pre- Follow Up Study
Item
Started Pre- Follow Up Study
boolean
Date Stopped
Item
Date Stopped
date
Continued Post- Follow Up Study
Item
Continued Post- Follow Up Study
boolean
Indication
Item
Conditions Treated / Indication
text
Item
Prophylaxis
text
concomitant medications intake
Code List
Prophylaxis
CL Item
Yes (Y)
CL Item
No (N)
Item
Was drug administered for an SAE?
text
concomitant medications intake
Code List
Was drug administered for an SAE?
CL Item
Yes (Y)
CL Item
No (N)
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial